JP2021522801A5 - - Google Patents
Info
- Publication number
- JP2021522801A5 JP2021522801A5 JP2020561908A JP2020561908A JP2021522801A5 JP 2021522801 A5 JP2021522801 A5 JP 2021522801A5 JP 2020561908 A JP2020561908 A JP 2020561908A JP 2020561908 A JP2020561908 A JP 2020561908A JP 2021522801 A5 JP2021522801 A5 JP 2021522801A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- fragment
- sequence
- cdrs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024059296A JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668824P | 2018-05-09 | 2018-05-09 | |
| US62/668,824 | 2018-05-09 | ||
| PCT/IL2019/050508 WO2019215728A1 (en) | 2018-05-09 | 2019-05-06 | Antibodies specific to human nectin4 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059296A Division JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522801A JP2021522801A (ja) | 2021-09-02 |
| JP2021522801A5 true JP2021522801A5 (enExample) | 2022-05-13 |
Family
ID=66690730
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561908A Pending JP2021522801A (ja) | 2018-05-09 | 2019-05-06 | ヒトネクチン４に特異的な抗体 |
| JP2024059296A Pending JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059296A Pending JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12077583B2 (enExample) |
| EP (1) | EP3790900A1 (enExample) |
| JP (2) | JP2021522801A (enExample) |
| KR (2) | KR102892725B1 (enExample) |
| CN (2) | CN119823267A (enExample) |
| AU (1) | AU2019264965B2 (enExample) |
| CA (1) | CA3097679A1 (enExample) |
| IL (1) | IL277858B1 (enExample) |
| WO (1) | WO2019215728A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| KR20210108978A (ko) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| CN113527486B (zh) * | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| CN115943312A (zh) | 2020-05-07 | 2023-04-07 | 法国居里学院 | 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途 |
| CN115768798A (zh) * | 2020-06-18 | 2023-03-07 | 生物蛋白有限公司 | 条件活性抗粘附分子-4(nectin-4)抗体 |
| EP4208259A2 (en) | 2020-09-04 | 2023-07-12 | NovaRock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
| EP4215546A4 (en) * | 2020-09-16 | 2025-02-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | ANTI-NECTIN-4 ANTIBODY, CONJUGATE THEREOF AND USE THEREOF |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| TW202302649A (zh) * | 2021-04-26 | 2023-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｎｅｃｔｉｎ－４抗體和抗ｎｅｃｔｉｎ－４抗體－藥物偶聯物及其醫藥用途 |
| KR20240026496A (ko) * | 2021-06-29 | 2024-02-28 | 엘피스 바이오파마슈티컬즈 | 항-넥틴4 항체 및 이를 포함하는 다중특이적 단백질 복합체 |
| US20250121090A1 (en) * | 2021-07-30 | 2025-04-17 | R.P. Scherer Technologies, Llc | Antibody-Drug Conjugates and Methods of Use Thereof |
| US20240366778A1 (en) * | 2021-08-27 | 2024-11-07 | Cspc Megalith Biopharmarceutical Co., Ltd. | Anti-nectin-4 antibody, drug conjugate, and preparation method therefor and use thereof |
| EP4463483A4 (en) * | 2022-01-12 | 2025-05-21 | Navi Bio-Therapeutics, Inc. | ANTIBODY SPECIFIC TO NECTIN CELL ADHESION MOLECULE 4 AND USES THEREOF |
| US20250205353A1 (en) | 2022-03-23 | 2025-06-26 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| WO2023198011A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Single domain anti-nectin-4 antibodies |
| WO2023198007A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Anti-nectin-4 antibodies and bispecific antibodies |
| CN116063498A (zh) * | 2022-04-27 | 2023-05-05 | 博际生物医药科技(杭州)有限公司 | 单域抗Nectin-4抗体 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| WO2024059733A2 (en) * | 2022-09-14 | 2024-03-21 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
| CN120239708A (zh) | 2022-09-20 | 2025-07-01 | 耐科廷疗法有限公司 | 针对黏连蛋白4的人源化抗体及其药物偶联物 |
| AU2023375625A1 (en) * | 2022-11-10 | 2025-05-15 | Century Therapeutics, Inc. | Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof |
| WO2024147891A1 (en) * | 2023-01-03 | 2024-07-11 | Harpoon Therapeutics, Inc. | Nectin4 targeting trispecific protein for treatment of cancer |
| CN116381251B (zh) * | 2023-03-13 | 2024-06-25 | 柏定生物工程(北京)有限公司 | 一种肿瘤标志物诊断试剂盒及其诊断方法 |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| EP4687991A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| CN116589584B (zh) * | 2023-05-24 | 2025-02-14 | 深圳市先康达生命科学有限公司 | 靶向人Nectin4蛋白的抗体或其片段和应用 |
| WO2024251260A1 (zh) * | 2023-06-08 | 2024-12-12 | 江苏迈威康新药研发有限公司 | 结合Nectin-4的抗体及其用途 |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025240789A1 (en) * | 2024-05-16 | 2025-11-20 | The Regents Of The University Of California | Chimeric antigen receptor targeting nectin4 |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4198507A (en) | 1978-11-13 | 1980-04-15 | Hoffmann-La Roche Inc. | Theophylline magnesium salicylate |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| DE69309472T2 (de) | 1992-01-23 | 1997-10-23 | Merck Patent Gmbh, 64293 Darmstadt | Fusionsproteine von monomeren und dimeren von antikörperfragmenten |
| EP0787185A2 (en) | 1994-10-20 | 1997-08-06 | MorphoSys AG | Targeted hetero-association of recombinant proteins to multi-functional complexes |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2222055A1 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Multimeric proteins |
| US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
| EP1103181A1 (de) | 1999-11-25 | 2001-05-30 | Novartis AG | Kombination der N-Phenyl-N'-Benzoyl Harnstoff Derivaten und Avermectin für Parasiten Kontrolle. |
| EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| US20090214517A1 (en) | 2004-07-27 | 2009-08-27 | Justin Wong | Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease |
| CA2672581A1 (en) * | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
| CA2825094C (en) * | 2011-01-18 | 2020-01-07 | Dalhousie University | Pvrl4 (nectin 4) is a receptor for measles virus. |
| HK1210964A1 (en) * | 2012-12-04 | 2016-05-13 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| MD4733C1 (ro) | 2014-08-19 | 2021-07-31 | Merck Sharp & Dohme Corp | Anticorpi anti-TIGIT |
| DK3653221T5 (da) | 2015-02-19 | 2024-08-26 | Compugen Ltd | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder |
| EP3344658B1 (en) | 2015-09-02 | 2022-05-11 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Antibodies specific to human t-cell immunoglobulin and itim domain (tigit) |
| EP3347048B1 (en) * | 2015-09-09 | 2020-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| CA3015619A1 (en) | 2016-03-01 | 2017-09-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human poliovirus receptor (pvr) |
| CN110392697A (zh) | 2017-03-02 | 2019-10-29 | 国家医疗保健研究所 | 对nectin-4具有特异性的抗体及其用途 |
| WO2022056304A1 (en) * | 2020-09-10 | 2022-03-17 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using nectin-4 specific fusion proteins |
-
2019
- 2019-05-06 KR KR1020207031656A patent/KR102892725B1/ko active Active
- 2019-05-06 CN CN202411898788.2A patent/CN119823267A/zh active Pending
- 2019-05-06 EP EP19728137.1A patent/EP3790900A1/en active Pending
- 2019-05-06 AU AU2019264965A patent/AU2019264965B2/en active Active
- 2019-05-06 WO PCT/IL2019/050508 patent/WO2019215728A1/en not_active Ceased
- 2019-05-06 CA CA3097679A patent/CA3097679A1/en active Pending
- 2019-05-06 IL IL277858A patent/IL277858B1/en unknown
- 2019-05-06 CN CN201980029788.XA patent/CN112088167B/zh active Active
- 2019-05-06 US US17/052,960 patent/US12077583B2/en active Active
- 2019-05-06 JP JP2020561908A patent/JP2021522801A/ja active Pending
- 2019-05-06 KR KR1020257039502A patent/KR20250173584A/ko active Pending
-
2024
- 2024-04-02 JP JP2024059296A patent/JP2024088696A/ja active Pending
- 2024-07-23 US US18/780,731 patent/US20240376202A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522801A5 (enExample) | ||
| AU2016281641B2 (en) | Novel PD-1 immune modulating agents | |
| JP2019511212A5 (enExample) | ||
| JP2022519341A5 (enExample) | ||
| JP2022515487A5 (enExample) | ||
| JP2021527431A5 (enExample) | ||
| JP2021531764A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2018532383A5 (enExample) | ||
| RU2018134065A (ru) | Антитела, специфические к рецептору полиовируса (pvr) человека | |
| JP2019533719A5 (enExample) | ||
| JP2020527332A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| CN108348521A (zh) | 用于治疗癌症的5-溴-2,6-二-(1h-吡唑-1-基)嘧啶-4-胺 | |
| FI3941946T3 (fi) | Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja | |
| JP2013519367A5 (enExample) | ||
| JP2022553922A5 (enExample) | ||
| JP2021512107A5 (enExample) | ||
| JP2021520201A5 (enExample) | ||
| JP2015509960A5 (enExample) | ||
| JP2021533796A5 (enExample) | ||
| JP2022512713A5 (enExample) | ||
| JP2025148452A5 (enExample) |